leucine has been researched along with Parkinson Disease in 50 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (4.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (14.00) | 29.6817 |
2010's | 15 (30.00) | 24.3611 |
2020's | 26 (52.00) | 2.80 |
Authors | Studies |
---|---|
Bendjebara, M; Damak, M; Farhat, N; Gargouri, A; Gharbi, A; Gouider, R; Kacem, I; Mhiri, C; Nasri, A; Sakka, S; Souissi, A; Zidi, S | 1 |
Bloodgood, DW; Chen, P; Ding, JB; Huang, G; Kaganovsky, K; Kang, J; Kim, JI; Shahapal, A; Shen, J | 1 |
Bryant, N; Bukhari, SA; Chartier-Harlin, MC; Chittoor-Vinod, VG; Cookson, MR; Fdez, E; Fernández, B; Hilfiker, S; Kelly, K; Kluss, JH; Lara Ordóñez, AJ; Montine, TJ; Moore, DJ; Nguyen, APT; Nichols, RJ; Smith, N; West, AB; Wilson, MA | 1 |
Al-Nusaif, M; Cheng, C; Le, W; Li, S; Liu, X; Wang, Y; Yu, H | 1 |
Greggio, E; Kluss, JH; Lewis, PA | 1 |
Chen, J; Chen, S; Luo, Q; Ma, J; Pan, J; Tang, H; Wang, P | 1 |
Alexander, A; Dolga, AM; Galuh, S; Kortholt, A; Oun, A; Sabogal-Guaqueta, AM | 1 |
Kim, YE; Kim, YJ; Lai, TT; Lee, YK; Ma, HI; Nguyen, HD; Nguyen, LTN; Nguyen, TT | 1 |
Chien, CT; Dewadas, HD; Foo, CN; Lim, YM; Lin, YE; Ravinther, AI; Tong, SR | 1 |
Fujino, Y; Kasai, T; Kitani-Morii, F; Menjo, K; Mizuno, T; Ohmichi, T; Shinomoto, M | 1 |
Amin, RP; Besteman, EG; Ciaccio, PJ; Gatto, NT; Glaab, WE; Gu, YZ; Kuruvilla, S; Lebron, J; Miller, G; Reynolds, SJ; Sistare, FD; Smith, R; Vlasakova, K; Wollenberg, G | 1 |
Groeneveld, GJ; Heuberger, JAAC; Huntwork-Rodriguez, S; Pereira, DR; Thijssen, E; Troyer, MD; Vissers, MFJM | 1 |
Kortholt, A; Zhang, X | 1 |
Herbst, S; Lewis, PA; Zhu, C | 1 |
Albus, A; Burg-Roderfeld, M; Dodel, R; Kronimus, Y; Ross, JA; van der Wurp, H; Willbold, D; Ziehm, T | 1 |
Cao, R; Chen, C; Shan, L; Sun, H; Sun, L; Wen, J; Wu, C; Xi, M; Yuan, L; Zhang, C; Zhao, W | 1 |
A, A; Ahmed, SS; K, S; Kumar, S; Kuriakose, B; Murugesan, R; Rs, AH; S, V; V, R | 1 |
Alcalay, RN; Bressman, S; Brumm, MC; Caspell-Garcia, C; Chahine, LM; Coffey, CS; Foroud, T; Galasko, D; Hutten, S; Kieburtz, K; Marek, K; Mollenhauer, B; Nudelman, K; Poston, K; Reimer, A; Seibyl, J; Shaw, LM; Siderowf, A; Simuni, T; Singleton, A; Tanner, CM; Toga, AW; Tosun-Turgut, D; Trojanowski, JQ; Uribe, L; Weintraub, D | 1 |
Datta, I; Jagtap, S; Pal, P; Potdar, C; Yadav, R | 1 |
Chen, J; Ge, YL; Gu, CC; Jin, H; Li, K; Liu, CF; Mao, CJ; Wang, F; Yang, YP; Zhang, JR; Zhang, YC | 1 |
Bonet-Ponce PhD, L; Cookson, MR | 1 |
Alcalay, RN; Baptista, MAS; Hutten, SJ; Joshi, N; Kang, MS; Kang, UJ; Kopil, K; Levers, N; Liong, C; Melachroinou, K; Narayan, S; Padmanabhan, S; Rideout, HJ; Stefanis, L | 1 |
Das, P; Halder, T; Joshi, D; Pandey, S; Raj, J; Sharma, V; Singh, RK; Verma, SP | 1 |
Azeggagh, S; Berwick, DC | 1 |
Beylina, A; Cookson, MR; Langston, RG; Reed, X; Rosen, D | 1 |
Ganesan, S; Heijjer, CN; Hwang, IY; Karlsson, MCI; Kehrl, JH; Nabar, NR; Shi, CS | 1 |
de Michele, G; de Rosa, A; Dubbioso, R; Esposito, M; Iodice, R; Manganelli, F; Peluso, S; Santoro, L | 1 |
Aarabi, MH; Ghazi Sherbaf, F; Same, K | 1 |
Roosen, DA; Singleton, AB | 1 |
Barichella, M; Bolliri, C; Caroli, D; Caronni, S; Cassani, E; Cereda, E; Ferrazzoli, D; Ferri, V; Frazzitta, G; Iorio, L; Maggio, M; Maras, A; Masiero, I; Ortelli, P; Pezzoli, G; Pinelli, G; Riboldazzi, G | 1 |
Sun, HM; Wang, ZZ; Zhang, Y | 1 |
Baekelandt, V; Bandopadhyay, R; Beilina, A; Belluzzi, E; Bubacco, L; Cirnaru, MD; Civiero, L; Cookson, MR; Greggio, E; Hondhamuni, G; Lewis, PA; Lobbestael, E; Piccoli, G; Reyniers, L; Rodella, U; Russo, I; Taymans, JM; Van den Haute, C | 1 |
de Boer, AH; Frijlink, HW; Grasmeijer, F; Hagedoorn, P; Luinstra, M; Moes, JR | 1 |
Dinelle, K; Ding, YS; Farrer, M; McKenzie, J; Schaffer, P; Sossi, V; Stoessl, AJ; Tsui, JK; Vafai, N; Wile, DJ | 1 |
An, R; Chen, Y; Tian, S; Xu, Y; Yang, X; Zhao, Q; Zheng, J | 1 |
Cookson, MR | 1 |
Cheng, L; Li, JY; Li, NN; Lu, ZJ; Peng, R; Sun, XY; Tan, EK; Wang, L; Zhang, JH | 1 |
Balck, A; Klein, C | 1 |
Borompokas, N; Bronstein, JM; Hadjigeorgiou, GM; Kanavouras, K; Latsoudis, H; Mastorodemos, V; Papapetropoulos, S; Plaitakis, A; Ritz, B; Skoula, I; Spanaki, C; Xiromerisiou, G; Zaganas, I | 1 |
Guo, JF; Pan, Q; Sun, QY; Tang, BS; Wang, L; Xia, K; Yao, LY; Yu, RH; Zuo, X | 1 |
Augustin, J; Ayrignac, X; Campion, D; Clanet, M; Coutant, S; Defebvre, L; Frébourg, T; Guyant-Maréchal, L; Hannequin, D; Krystkowiak, P; Labauge, P; Le Ber, I; Lefaucheur, R; Legallic, S; Maltête, D; Martinaud, O; Nicolas, G; Pariente, J; Pottier, C; Rousseau, S; Rovelet-Lecrux, A; Vaschalde, Y | 1 |
Anvret, M; Buervenich, S; Carmine, A; Olson, L; Sydow, O | 1 |
Clarimon, J; Eerola, J; Hellström, O; Singleton, A; Tienari, PJ | 1 |
Aasly, JO; Farrer, MJ; Pielsticker, L; Ross, OA; Toft, M | 1 |
Chen, S; Deng, X; Ding, X; Dong, H; Li, W; Li, X; Ma, G; Wu, T; Yao, J; Zeng, Y; Zhang, X | 1 |
Annesi, F; Annesi, G; Carrideo, S; Cirò Candiano, IC; Civitelli, D; Condino, F; De Marco, EV; Messina, D; Morelli, M; Nicoletti, G; Novellino, F; Provenzano, G; Quattrone, A; Rocca, FE; Tarantino, P | 1 |
Bird, TD; Griffith, A; Leis, BC; Leverenz, JB; Mata, IF; Roberts, JW; Samii, A; Schellenberg, GD; Schneer, SH; Sidransky, E; Tsuang, D; Zabetian, CP | 1 |
Bock, H; Hilbig, A; Jardim, LB; Michelin-Tirelli, K; Rieder, CR; Saraiva-Pereira, ML; Socal, MP | 1 |
Chase, TN; Lipton, MA; Morris, CE; Woods, AC | 1 |
Barbeau, A; Kastin, AJ | 1 |
10 review(s) available for leucine and Parkinson Disease
Article | Year |
---|---|
Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease.
Topics: Animals; Drug Design; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Parkinson Disease | 2022 |
The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids.
Topics: Aged; Humans; Induced Pluripotent Stem Cells; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Neurodegenerative Diseases; Organoids; Parkinson Disease | 2022 |
Role of NLRP3 Inflammasome in Parkinson's Disease and Therapeutic Considerations.
Topics: alpha-Synuclein; Cytokines; Humans; Inflammasomes; Inflammation; Leucine; Neurodegenerative Diseases; NLR Family, Pyrin Domain-Containing 3 Protein; Nucleotides; Parkinson Disease | 2022 |
Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.
Topics: Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Neurodegenerative Diseases; Parkinson Disease | 2022 |
LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
Topics: GTP Phosphohydrolases; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases | 2023 |
Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
Topics: Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Neurodegenerative Diseases; Parkinson Disease; Protein Serine-Threonine Kinases | 2023 |
Association of leucine-rich repeat kinase 2 gene rs10878307 polymorphism and Parkinson's disease risk in South India-A meta-analysis and molecular dynamics simulation.
Topics: Humans; India; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Molecular Dynamics Simulation; Parkinson Disease; Protein Serine-Threonine Kinases | 2020 |
The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.
Topics: Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease | 2022 |
A meta-analysis of the relationship of the Parkin p.Val380Leu polymorphism to Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Heterozygote; Homozygote; Humans; Leucine; Male; Middle Aged; Odds Ratio; Parkinson Disease; Polymorphism, Genetic; Ubiquitin-Protein Ligases; Valine | 2013 |
Mutational scanning of the CHCHD2 gene in Han Chinese patients with Parkinson's disease and meta-analysis of the literature.
Topics: Adult; Aged; Asian People; DNA Mutational Analysis; DNA-Binding Proteins; Genetic Association Studies; Genotype; Humans; Leucine; Middle Aged; Mitochondrial Proteins; Mutation; Parkinson Disease; Proline; Transcription Factors | 2016 |
1 trial(s) available for leucine and Parkinson Disease
Article | Year |
---|---|
Muscle-targeted nutritional support for rehabilitation in patients with parkinsonian syndrome.
Topics: Aged; Amino Acids, Essential; Body Weight; Cholecalciferol; Dietary Proteins; Dietary Supplements; Female; Food, Fortified; Humans; Leucine; Male; Middle Aged; Muscle, Skeletal; Nutritional Support; Parkinson Disease; Parkinsonian Disorders; Physical Functional Performance; Treatment Outcome; Vitamins; Walk Test; Walking Speed; Whey Proteins | 2019 |
39 other study(ies) available for leucine and Parkinson Disease
Article | Year |
---|---|
Heart rate variability and sympathetic skin response for the assessment of autonomic dysfunction in leucine-rich repeat kinase 2 associated Parkinson's disease.
Topics: Cross-Sectional Studies; Female; Heart Rate; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Mutation; Parkinson Disease; Primary Dysautonomias | 2022 |
Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice.
Topics: Animals; Dopamine; Dopaminergic Neurons; Female; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Mice; Mice, Knockout; Motor Disorders; Parkinson Disease | 2022 |
Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity.
Topics: Animals; Fibroblasts; HEK293 Cells; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mutation; Parkinson Disease; Phosphorylation; rab GTP-Binding Proteins; Rats; Reproducibility of Results | 2022 |
Altered Motor Performance, Sleep EEG, and Parkinson's Disease Pathology Induced by Chronic Sleep Deprivation in Lrrk2
Topics: alpha-Synuclein; Animals; Electroencephalography; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Transgenic; Mutation; Parkinson Disease; Sleep Deprivation | 2022 |
A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease.
Topics: China; Heterozygote; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease | 2022 |
Serum leucine-rich α2 glycoprotein as a potential biomarker for systemic inflammation in Parkinson's disease.
Topics: Animals; Biomarkers; Dementia; Glycoproteins; Inflammation; Leucine; Parkinson Disease | 2023 |
Early-Onset albuminuria and Associated Renal Pathology in Leucine-Rich Repeat Kinase 2 Knockout Rats.
Topics: Albuminuria; Animals; Biomarkers; Female; Kidney; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Mice; Mice, Knockout; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Rats; Rats, Long-Evans | 2023 |
A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
Topics: Biomarkers; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Leukocytes, Mononuclear; Mutation; Parkinson Disease | 2023 |
Leucine-rich repeat kinase 2 at a glance.
Topics: Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease | 2023 |
The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson's Disease.
Topics: alpha-Synuclein; Autoantibodies; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease | 2023 |
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Topics: Cross-Sectional Studies; Disabled Persons; Dopamine Plasma Membrane Transport Proteins; Glucosylceramidase; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Longitudinal Studies; Motor Disorders; Mutation; Parkinson Disease | 2020 |
Generation of induced pluripotent stem cells (NIMHi001-A) from a Parkinson's disease patient of East Indian ethnicity carrying LRRK2 I1371V variant.
Topics: Ethnicity; Humans; Induced Pluripotent Stem Cells; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Leukocytes, Mononuclear; Mutation; Parkinson Disease | 2020 |
Substantia nigra hyperechogenicity in Parkinson disease patients with leucine-rich repeat kinase 2 variants in the Chinese Han population.
Topics: China; Humans; Leucine; Parkinson Disease; Substantia Nigra; Ultrasonography, Doppler, Transcranial | 2020 |
Can Leucine-Rich Repeat Kinase 2 Inhibition Benefit GBA-Parkinson's Disease?
Topics: Glucosylceramidase; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease | 2020 |
Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine-Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme-Linked Immunosorbent Assay-Based Method.
Topics: Enzyme-Linked Immunosorbent Assay; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Leukocytes, Mononuclear; Mutation; Parkinson Disease | 2020 |
Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease.
Topics: Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease; Ubiquitin-Protein Ligases | 2020 |
Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).
Topics: Cell Line; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases | 2021 |
LRRK2 is required for CD38-mediated NAADP-Ca
Topics: Adenosine Diphosphate Ribose; Antibodies, Monoclonal; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Calcium; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lipopolysaccharides; Lysosomes; NADP; Parkinson Disease; Transcription Factors | 2022 |
Does motor cortex plasticity depend on the type of mutation in the leucine-rich repeat kinase 2 gene?
Topics: Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Motor Cortex; Mutation; Parkinson Disease | 2017 |
New link between Parkinson's and Alzheimer's: Research uncovers the role of mutant leucine rich repeat kinase 2 and amyloid precursor protein.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Parkinson Disease; Phosphorylation | 2017 |
Leucine rich repeat kinase knockout (LRRK KO) mouse model: Linking pathological hallmarks of inherited and sporadic Parkinson's disease.
Topics: Animals; Autophagy; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Knockout; Parkinson Disease | 2018 |
Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.
Topics: Actin Cytoskeleton; Animals; Brain; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mammals; Mice; Mutation; Neurites; p21-Activated Kinases; Parkinson Disease; Protein Serine-Threonine Kinases | 2015 |
A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods.
Topics: Administration, Inhalation; Aerosols; Antiparkinson Agents; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Dry Powder Inhalers; Excipients; Humans; Leucine; Levodopa; Parkinson Disease; Reproducibility of Results; Tissue Distribution | 2015 |
A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.
Topics: Brain; Dopamine; Female; Heterozygote; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Middle Aged; Mutation; Parkinson Disease; Positron-Emission Tomography; Radionuclide Imaging | 2016 |
Structure, function, and leucine-rich repeat kinase 2: On the importance of reproducibility in understanding Parkinson's disease.
Topics: Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Reproducibility of Results | 2016 |
Genetic analysis of CHCHD2 gene in Chinese Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Asian People; China; DNA-Binding Proteins; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genetic Testing; Genotype; Humans; Leucine; Male; Middle Aged; Mitochondrial Proteins; Mutation; Parkinson Disease; Proline; Risk Factors; Transcription Factors | 2016 |
Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection.
Topics: Humans; Leucine; Mutation; Parkinson Disease; Penetrance; Protein Serine-Threonine Kinases | 2017 |
Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset.
Topics: Adenosine Diphosphate; Age of Onset; Aged; Biocatalysis; California; Cohort Studies; Demography; Diethylstilbestrol; Female; Glutamate Dehydrogenase; Greece; Guanosine Triphosphate; Humans; Leucine; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Recombinant Proteins | 2010 |
Glucocerebrosidase gene L444P mutation is a risk factor for Parkinson's disease in Chinese population.
Topics: Adult; Asian People; Case-Control Studies; Chi-Square Distribution; DNA Mutational Analysis; Female; Glucosylceramidase; Humans; Leucine; Male; Meta-Analysis as Topic; Middle Aged; Mutation; Parkinson Disease; Proline | 2010 |
Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification.
Topics: Adult; Aged; Amino Acid Substitution; Arginine; Basal Ganglia Diseases; Calcinosis; Child; Databases, Genetic; Exome; Female; Humans; Leucine; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neurologic Examination; Parkinson Disease; Pedigree; Polymerase Chain Reaction; Proline; Receptor, Platelet-Derived Growth Factor beta; Tomography, X-Ray Computed; Tryptophan | 2013 |
Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease.
Topics: Adult; Aged; Alleles; Amino Acid Substitution; Aryldialkylphosphatase; Esterases; Female; Gene Frequency; Genotype; Humans; Leucine; Lipid Peroxidation; Male; Methionine; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Reference Values; Sweden | 2002 |
Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Aryldialkylphosphatase; Case-Control Studies; DNA Mutational Analysis; Female; Finland; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glutamine; Humans; Leucine; Male; Methionine; Middle Aged; Parkinson Disease; Polymorphism, Genetic | 2004 |
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population.
Topics: Adult; Aged; Aged, 80 and over; Asparagine; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Glucosylceramidase; Heterozygote; Humans; Leucine; Male; Middle Aged; Mutation; Parkinson Disease; Proline; Serine | 2006 |
A novel P755L mutation in LRRK2 gene associated with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Leucine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Mutation; Parkinson Disease; Proline; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy.
Topics: Aged; Asparagine; DNA Mutational Analysis; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glucosylceramidase; Humans; Italy; Leucine; Male; Middle Aged; Mutation; Parkinson Disease; Proline; Serine | 2008 |
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.
Topics: Aged; Asparagine; Case-Control Studies; DNA Mutational Analysis; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glucosylceramidase; Humans; Leucine; Lewy Body Disease; Male; Middle Aged; Mutation; Parkinson Disease; Proline; Risk Factors; Serine | 2008 |
Parkinson's disease and the heterozygous state for glucocerebrosidase mutations among Brazilians.
Topics: Adult; Asparagine; Brazil; Female; Glucosylceramidase; Heterozygote; Humans; Leucine; Male; Middle Aged; Mutation; Parkinson Disease; Proline; Serine | 2009 |
Hypothalamic releasing factors and Parkinson disease.
Topics: Antiparkinson Agents; Depression, Chemical; Dihydroxyphenylalanine; Drug Therapy, Combination; Glycine; Humans; Leucine; Melanocyte-Stimulating Hormones; Oligopeptides; Parkinson Disease; Pituitary Hormone-Releasing Hormones; Proline; Thyrotropin-Releasing Hormone | 1974 |
Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
Topics: Administration, Oral; Aged; Amides; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Glycine; Humans; Injections, Intravenous; Leucine; Male; Middle Aged; Movement Disorders; Parkinson Disease; Peptides; Proline | 1972 |